AMGN

Amgen
Biotechnology · Health Care · as of 2026-11-20
Last close
$439.61
+0.8% on the session
1-year return
+32.8%
+31.1% over six months
Volatility
28.9%
annualized, trailing year
Max drawdown
-16.6%
worst peak to trough, 1y
What the numbers say

Amgen is a biotechnology name in the health care sector. Over the past year it returned +32.8%, against -0.4% over three months and -1.1% over one. It trades 16.0% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 28.9% is moderate by single-stock standards.

Its worst peak-to-trough decline over the year was -16.6%, and it has traded a median $1.1B a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.24 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#24 of 59
Stronger than 60% of its sector on the momentum profile
Across the whole index#91 of 497

How AMGN scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.

Start a free 7-day trial
Full metrics
1 day+0.8%
1 week-5.1%
1 month-1.1%
3 months-0.4%
6 months+31.1%
1 year+32.8%
12-1 momentum+34.3%
Volatility (1y, annualized)28.9%
Max drawdown (1y)-16.6%
Distance vs 200-day average+16.0%
Return per unit of risk1.13
Median daily dollar volume$1.1B
Free newsletter

Get AMGN when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.